DaVita Inc.

NYSE:DVA

Medical - Care Facilities

Healthcare
$161.79 +0.77%

+$1.60 today

Market cap
$10.18B
Beta
0.91
P/E (TTM)
18.2
EPS (TTM)
$11.60
52W Low $101.00High $213.44

Volume 1.12M

Average 0.84M

DVA Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

DaVita Inc.NYSE: DVA

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development remains negative

Q2 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.

Context

  • Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMJun 2026
$0— YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Research & Development vs competitors

How DVA compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Research & development amounts to 0.0% of revenue for DVA, versus a peer median of 2.6%.
DVA Competitors
Research & Development for DVA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BAXBaxter International Inc.LTM Jun 2026$512M USD-16.6%+4.8%4.5%
FMSFresenius Medical Care AG & Co. KGaALTM Jun 2026€154.32M EUR-10.1%-11.6%0.8%
DVADaVita Inc.LTM Jun 2026$0 USD——0.0%
Peer median (excluding DVA) —-13.4%-3.4%2.6%

Competitors are the stored peer set for DVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue11.62B11.61B12.14B12.82B13.64B
Cost of Revenue7.97B8.21B8.32B8.6B9.96B
Gross Profit3.65B3.4B3.82B4.22B3.68B
Gross Margin31.4%29.3%31.5%32.9%27.0%
Research & Development00000
Selling, General & Admin1.2B1.36B1.47B1.54B1.67B
Operating Expenses1.85B2.06B2.22B2.13B1.67B
Depreciation & Amortization680.62M732.6M745.44M723.86M715.35M
EBITDA2.48B2.06B2.32B2.72B2.64B
EBITDA Margin21.4%17.7%19.1%21.3%19.4%
Operating Income1.8B1.34B1.6B2.09B2.01B
Operating Margin15.5%11.5%13.2%16.3%14.7%
Interest Income00000
Interest Expense285.25M357.02M398.55M470.47M549.67M
Other Income / Expenses(278.88M)(372.78M)(425.69M)(560.09M)(663.79M)
Income Before Tax1.52B966.28M1.18B1.53B1.35B
Pre-Tax Margin13.1%8.3%9.7%11.9%9.9%
Income Tax Expense306.73M198.09M220.12M279.66M293.11M
Net Income978.45M560.4M691.54M936.34M746.8M
Net Margin8.4%4.8%5.7%7.3%5.5%
EPS (Basic)9.305.887.6211.029.72
EPS (Diluted)8.905.717.4210.739.51
Weighted Avg Shares105.23M92.99M90.79M84.99M86.1M
Weighted Avg Shares (Diluted)109.95M95.83M93.18M87.27M88.1M

DaVita Inc.

NYSE:DVA

Intrinsic Alpha fair value

Locked

Current Price

$161.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.